NOW Health Network’s Post

Name: NOW Health Network on LinkedIn: NOW Health Network: What is Prostate Cancer Dr. Kevin Zorn, MD, FRCSC…
Uploaded: 2024-10-15T13:39:29.127Z
Duration: 3 min 9 s
Channel: NOW Health Network

NOW Health Network

941 followers

1mo

NOW Health Network: What is Prostate Cancer Dr. Kevin Zorn, MD, FRCSC, FACS, Urologist : Prostate cancer is the most common male cancer diagnosed in Canada—one out of every eight men will develop it in their lifetime. Prostate cancer starts in the cells of the prostate, and can grow into nearby tissue. The cancerous tumour can also spread (metastasize) to other parts of the body. https://lnkd.in/gVjV7qxq

Transcript

Prostate cancer is the most common male cancer diagnosed in Canada. One out of every eight men will develop it in their lifetime. Prostate cancer starts in the cells of the prostate and can grow into nearby tissues. The cancerous tumor can also spread or metastasize to other parts of the body. The prostate is a walnut sized organ that sits below the bladder. It surrounds the passage that carries urine from the bladder through the penis during urination. This tube is called the urethra. The prostate functions to support male fertility. Its secrets fluid which forms some of the seamen in which sperm are transported. Health experts don't know the exact cause of prostate cancer. However, risk factors include family history. If you have a father or a brother who has had prostate cancer, your risk of developing disease increases. Race. Men of African ancestry appear to have highest risk of getting prostate cancer. Asian men have the lowest risk. Age. As men get older, their risk of prostate cancer gets higher. Newly diagnosed prostate cancer often occurs in men over the age of 60. In Canada, most prostate cancer is found due to abnormalities of the PSA Prostate specific antigen test. The PSA test is usually given to men over the age of 50 to assess for prostate cancer risk. The higher the PSA levels, the greater the risk you have of developing prostate cancer. Since most prostate cancers grow on the outside layer of the prostate called the peripheral zone, doctors may also feel a lump during their digital rectal exam. A digital rectal exam can be an important step in diagnosing prostate cancer. It can also determine how big or aggressive the prostate cancer is. Contrary to what you may have seen on a TV show or in a movie, a diary isn't painful. The most common type of cancer that starts in the prostate is called adenocarcinoma. This type of cancer comprises over 95% of prostate cancers. Most men who are diagnosed with prostate cancer have no symptoms it. If an abnormality is found in your prostate either by the PSA test and or a Dre, a visitation will order a prostate biopsy. The tissue from the biopsy prostate can be assessed for prostate cancer under a microscope. In Canada, this is the most commonly done through the ****** with an ultrasound. However, it can also be performed in the space between the scrotum and the ****** otherwise called the perineum. If you have prostate cancer, hormone therapy, active surveillance, surgery, radiation or chemotherapy may be part of your treatment plan. For more information, speak to your family physician to get consultation to your local urologist.

To view or add a comment, sign in

More Relevant Posts

Erika Wirth

Recruiter Sales, Marketing, and Executive Talent Acquisition
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Salah (Sal) Dagher

Senior Director Business Development at Labcorp
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Iqbal Gandhi

Central Laboratory Services | Non-Clinical | Clinical Phase I-IV | Preclinical | Early Development | Business Development | Inside Sales
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Stephanie Carter

Oncology • Pathology • Precision Medicine • Lab Partnerships
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Sriram R

Associate Director Oncology Biomarkers
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Jessica Monràs

Business Development Director
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Ryan Heidel

Business Development Manager | Inside Sales at Labcorp | Preclinical Oncology | Discovery
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Dr.Manoj Pujari

Proposal Associate at Labcorp
9mo
Report this post
Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curing #cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from the European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow-up after discontinuation of cancer treatment. #NationalCancerPreventionMonth

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

learn-more.com
Like Comment
To view or add a comment, sign in
Ohio Gastroenterology Group, Inc.

1,073 followers
8mo
Report this post
Colonoscopies can both help detect and prevent colorectal cancer. The most common type of colorectal cancer starts as precancerous polyps or adenomas, which can be easily detected and removed during a colonoscopy before they become cancers. Learn more about colon cancer at https://lnkd.in/gD7kwmhZ #coloncancer #colorectalcancer #coloncancerawareness #colorectalcancerawareness #coloncancerprevention #rectalcancer #RectalCancerAwareness

1 Comment
Like Comment
To view or add a comment, sign in
Dr. Omon Imohi MD CCFP FRCGP DFSRH

Multiple award-winning Family Physician | Health Content Creator | Health Empowerment | Speaker | WHO Fides Member | Passionate about transforming lives
1mo Edited
Report this post
Don’t miss out on these important screening tests! If you’re due and eligible, this is your reminder to schedule your appointment. ➡️ Breast Cancer: Mammograms (40+) ➡️ Cervical Cancer: Pap smear (21+) ➡️ Colorectal Cancer: FIT/Colonoscopy (45+) ➡️ Lung Cancer:Screening for high-risk (smokers, 55+) ➡️ Prostate Cancer:Talk to your doctor (45+) Early detection saves lives! Stay proactive 💪🏾💪🏾 #CancerAwareness #Screening #Cancerscreening #Earlydetection #whofides #breastcancer #breastcancerawarenessmonth

4 Comments
Like Comment
To view or add a comment, sign in

941 followers

View Profile Follow

NOW Health Network’s Post

Transcript

More Relevant Posts

Explore topics